Company profile
MADRIGAL PHARMACEUTICALS, INC.
NASDAQ:MDGLBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Resmetirom | approved | — | 17 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04197479 | phase3 | completed | 2019-12-16 | 2023-01-06 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients |
| NCT04951219 | phase3 | active_not_recruiting | 2021-07-09 | 2027-03-01 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) |
| NCT05500222 | phase3 | active_not_recruiting | 2022-08-26 | 2026-12-01 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) |
| NCT03900429 | phase3 | active_not_recruiting | 2019-03-28 | 2028-01-01 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis |
| NCT06397872 | phase1 | completed | 2024-03-06 | 2024-09-16 | Madrigal Pharmaceuticals, Inc. | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 217785 | NDA | MADRIGAL PHARMACEUTICALS INC | ||||
Loading… | ||||||